Jentadueto combination diabetes drug gets European approval

The European Commission (EC) has approved the oral type 2 diabetes medication Jentadueto, which combines metformin with the DPP-4 inhibitor, linagliptin (Trajenta) in a single tablet.
The EC has given the green light for Jentadueto to specifically be used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes who are unable to adequately control blood sugar through the use of metformin alone, metformin and a sulphonylurea, as well as those already being treated with separate doses of linagliptin and metformin .
Pharmaceutical giants Boehringer Ingelheim and Eli Lilly, which produce the drug, have received marketing authorisation from the EC and will now be able to offer the product as a new, twice-daily treatment option for type 2 diabetics across Europe.
“We’re delighted that linagliptin/metformin hydrochloride (HCl) will soon be available across Europe to help people with type 2 diabetes,” said Professor Klaus Dugin, head of medicine at Boehringer Ingelheim.
“Many patients need more than one treatment to adequately manage their diabetes. Linagliptin/metformin hydrochloride (HCl) offers a simplified, single tablet dosing option, to improve glycemic control and with a favourable side effect profile.”